Rolex for $150, Chanel for $1,200, Hermes' Birkin for $1,400: we get you the details on China's rebuttal to Trump's tariffs. Medical experts have officially recognised a lesser-known diabetes ...

Diabetes and prediabetes were significantly associated with decreased life expectancy and increased risk for all-cause, cardiovascular disease and cancer mortality among Chinese adults, according ...

China's Diabetes Device market is expected to reach US$ 6.22 Billion in 2023 to US$ 12.74 Billion by 2032, with a CAGR of 8.30 % from 2024 to 2032. Recent decades have seen a sharp increase in the ...

World-First Stem Cell Treatment Reverses Diabetes for a Patient in China, Study Suggests Scientists converted the patient’s own cells into blood sugar-regulating cell clusters before injecting ...

Xinhua | Updated: 2024-07-30 10:38 [Photo/IC] BEIJING -- China on Monday released two guidelines for the prevention and treatment of diabetes and chronic respiratory diseases from 2024 to 2030.

The China diabetes market size reached US$ 4.7 Billion in 2023 and is forecast to reach US$ 9.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2023-2032.

Chinese scientists cured type 2 diabetes using islet cell transplantation at Shanghai Changzheng Hospital. Blood-to-islet cell transformation in July 2021 ended T2D in a 59-year-old. Published in ...

Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic. This move signals a significant expansion in the Asian market, where GLP-1 ...

Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market.

The China Diabetes Care Drugs Market is currently experiencing significant growth and is predicted to attain a valuation of USD 13.73 billion by 2028, ascending at a compound annual growth rate ...